Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Researchers Discover Drug Target For Osteoporosis, Rheumatoid Arthritis

This article was originally published in PharmAsia News

Executive Summary

A team led by osteo-immunology professor, Hiroshi Takayanagi, of Tokyo Medical and Dental University, found two enzymes in osteoclastic cells that cause osteoporosis and rheumatoid arthritis. If inhibitors inside the human body can be developed to constrain the enzymes, the research could lead to the discovery of treatments for the diseases. By analyzing DNA of the cells, the team found that the enzyme Btk and Tec are responsible for building the cells. After compounds that constrain the two enzymes were given to a mouse, symptoms of osteoporosis and rheumatoid arthritis improved. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts